oxaliplatin / Generic mfg. |
| Completed | 2b | 198 | US, Europe, RoW | Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) | Bayer, Amgen | Metastatic Colorectal Cancer | 01/11 | 02/12 | | |
|
NCT00065117: Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 180 | US | ZD6126, Placebo, 5-fluorouracil, leucovorin, oxaliplatin | AstraZeneca | Colorectal Neoplasms, Metastases, Neoplasm | 02/04 | 02/04 | | |
NCT00120172: Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 40 | US | oxaliplatin, capecitabine, bevacizumab | Geriatric Oncology Consortium, Sanofi | Colorectal Cancer, Neoplasm Metastasis | | 06/06 | | |
NCT00123851: Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 32 | US | Tarceva (OSI-774), Capecitabine, Oxaliplatin | Dana-Farber Cancer Institute, Sanofi-Synthelabo, OSI Pharmaceuticals, Hoffmann-La Roche, Genentech, Inc., Massachusetts General Hospital, Beth Israel Deaconess Medical Center | Colorectal Cancer, Neoplasm Metastasis | 08/06 | 08/06 | | |
NCT00353145: Gemox as First and Second Line Therapy in Unknown Primary Cancer |
|
|
| Completed | 2 | 29 | US | Gemcitabine (Gemox), Gemcitabine Hydrochloride, Gemzar, Oxaliplatin, Eloxatin, Questionnaire | M.D. Anderson Cancer Center, Sanofi-Synthelabo | Unknown Primary Neoplasms | 03/07 | 01/10 | | |
NCT00083616: Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy |
|
|
| Completed | 2 | 185 | US | Panitumumab, ABX-EGF, Vectibix | Amgen | Colorectal Cancer, Metastatic Cancer | 05/07 | 12/08 | | |
NCT00346099: Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum |
|
|
| Withdrawn | 2 | 0 | US | Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by, Panitumumab with capecitabine and radiation | NSABP Foundation Inc, Amgen | Rectal Cancer, Neoplasm Metastasis | | 05/07 | | |
NCT00193609: Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site |
|
|
| Completed | 2 | 48 | US | Oxaliplatin, Eloxatin, Capecitabine, Xeloda | SCRI Development Innovations, LLC, Roche Pharma AG, Sanofi-Synthelabo | Neoplasms, Unknown Primary | 04/08 | 01/09 | | |
NCT00408772: Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation | University of California, Davis, Sanofi | Colorectal Cancer, Metastatic Cancer | 04/08 | 04/08 | | |
NCT00508872: Folfox-B Study for Patients With Colorectal Liver Metastases |
|
|
| Terminated | 2 | 2 | US | 5-Fluorouracil, 5-FU, Adrucil, Efudex, Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Leucovorin, Citrovorum, Wellcovorin, Oxaliplatin, Eloxatin | M.D. Anderson Cancer Center, Sanofi | Colorectal Liver Metastases | 06/09 | 06/09 | | |
NCT00557206: Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer |
|
|
| Terminated | 2 | 35 | US | Oxaliplatin and Docetaxel | Minneapolis Veterans Affairs Medical Center, Sanofi | Neoplasms, Head and Neck Neoplasms | 11/09 | 11/09 | | |
NCT01022541 / 2005-004505-29: Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 47 | Europe | Capecitabine, Xeloda, Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Liver metastasectomy | Royal Marsden NHS Foundation Trust, Roche Pharma AG | Metastatic Colorectal Cancer | 12/10 | 02/15 | | |
|
|
HEARTO, NCT01348412: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure |
|
|
| Completed | 2 | 31 | Europe | oxaliplatin, raltitrexed, other intravenous chemotherapy drugs | Centre Georges Francois Leclerc, National Cancer Institute, France, Hospira, now a wholly owned subsidiary of Pfizer | Colorectal Cancer, Liver Metastases | 12/10 | 04/18 | | |
APRIORI, NCT01126866: Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy |
|
|
| Terminated | 2 | 35 | Europe | intensified chemotherapy (FOLFOXIRI/Bevacizumab) | National Center for Tumor Diseases, Heidelberg, Roche Pharma AG, Pfizer | Colorectal Carcinoma | 03/11 | 06/11 | | |
| Completed | 2 | 268 | Europe, RoW | aflibercept, ZALTRAP™, AVE0005, oxaliplatin, 5-FU, Folinic Acid | Sanofi | Colorectal Neoplasms, Neoplasm Metastasis | 04/11 | 01/12 | | |
|
NCT00700570: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 45 | RoW | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 11/11 | 11/11 | | |
| Withdrawn | 2 | 0 | Canada | irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab | Ottawa Hospital Research Institute, Hoffmann-La Roche, Sanofi | Metastatic Colorectal Cancer | 02/12 | 02/12 | | |
| Completed | 2 | 171 | US, Europe, RoW | CT-011, FOLFOX | Medivation, Inc. | Metastatic Colorectal Cancer | 05/12 | 03/13 | | |
|
NCT01703910 / 2012-001307-20: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
|
|
| Completed | 2 | 29 | Europe | Arm A chemotherapy, Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil, Gemcitabine, Irinotecan, Topotecan, Mitomycin C, Oxaliplatin, Paclitaxel, Docetaxel, Pemetrexed, Raltitrexed, Sorafenib, Erlotinib, Vinorelbine, Dasatinib, Etoposide, arm B chemotherapy | Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Grupo Hospital de Madrid, Apices Soluciones S.L. | Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease | 11/12 | 12/14 | | |
| Completed | 2 | 80 | Europe | 5-FU, Irinotecan, Leucovorin, Oxaliplatin, bevacizumab [Avastin] | Hoffmann-La Roche | Colorectal Cancer | 10/13 | 10/13 | | |
|
| Completed | 2 | 60 | US | capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) | Duke University, Hoffmann-La Roche, Sanofi, Genentech, Inc. | Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis | 01/14 | 07/14 | | |
|
NCT01226719: FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only |
|
|
| Completed | 2 | 15 | US | Panitumumab, Combined Modality Treatment, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil | SCRI Development Innovations, LLC, Amgen | Colorectal Cancer | 03/14 | 03/14 | | |
|
| Completed | 2 | 77 | Europe | 5-Fluorouracil (5-FU), Bevacizumab, Avastin, Levofolinic acid, Oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 05/14 | 05/16 | | |
| Completed | 2 | 80 | Europe | Panitumumab+FOLFOX-4, Panitumumab+FOLFIRI | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Amgen | Colorectal Cancer | 03/15 | 03/15 | | |
|
|
|
|
PREVIUM, NCT02175654 / 2014-000703-26: Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab |
|
|
| Terminated | 2 | 15 | Europe | Regorafenib | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Bayer | Colorectal Neoplasms, Metastatic Disease | 02/16 | 02/16 | | |
| Terminated | 2 | 44 | Europe | FOLFOX6, Chemotherapy, Bevacizumab, Avastin, Panitumumab, Vectibix, Surgery | European Organisation for Research and Treatment of Cancer - EORTC, Amgen, Roche Pharma AG | Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer | 09/16 | 09/16 | | |
|
VISNU-2, NCT01640444 / 2012-000840-90: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) |
|
|
| Completed | 2 | 240 | Europe | FOLFIRI + bevacizumab, FOLFIRI + cetuximab | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Roche Pharma AG | Colorectal Cancer Metastatic | 11/18 | 11/18 | | |
NCT00494221: A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX |
|
|
| Completed | 1/2 | 172 | Japan | AZD2171, cediranib, RECENTIN™, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Eloxatin®, 5-FU, Leucovorin, Placebo Cediranib | AstraZeneca | Metastatic Colorectal Cancer | 10/09 | 08/12 | | |
|
NCT01632306: A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer |
|
|
| Terminated | 1/2 | 13 | US | LY2090314, FOLFOX, FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin), Gemcitabine, Gemzar, LY188011, Nab-paclitaxel | Eli Lilly and Company, Mayo Clinic | Pancreatic Cancer | 06/15 | 06/15 | | |
ACTION, NCT02273713: The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma |
|
|
| Completed | 1/2 | 154 | Europe | Nab-paclitaxel, Abraxane | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Celgene Corporation | Esophageal Cancer, Toxicity | 03/17 | 03/17 | | |